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INTRODUCTION
Immunization using DC loaded with tumor antigens is a potentially powerful method of inducing antitumor immunity 1 . An effective way of loading DC with tumor antigen is to transduce the DC with recombinant viral vectors or to transfect with mRNA encoding tumor antigens 2 . CD8 + cytotoxic T cells (CTL) are an important effector arm in the antitumor immune response and the induction of potent CTL responses has been the main goal in developing immunotherapeutic strategies for cancer 3, 4 . Accumulating evidence, however, suggest that the CD4 + T cell response also plays a key role in tumor immunity 5, 6 . CD4 + T cells provide important functions for the induction, expansion and persistence of CD8 + CTL 7 . Secretion of effector cytokines such as IFN by CD4 + T cells sensitizes tumor cells to CTL lysis via upregulation of MHC class I molecules, stimulates the innate arm of the immune system at the tumor site and, as was recently suggested, inhibits local angiogenesis 8 . The importance of the CD4 + T cell response in tumor immunity was highlighted in murine studies showing that CD4 + T cells can eradicate tumor in the absence of CD8 + T cells [9] [10] [11] or constitute the dominant effector arm in the antitumor response 12 . Therefore, an optimal antitumor immune response will require the concomitant activation of both CD4 + and CD8 + T cells.
Endogenously expressed antigens, such as antigens expressed in DC transfected with mRNA, will be channeled preferentially into the class I processing pathway to activate the CD8 + T cell arm of the immune response 13 
Peptides and oligonucleotides (ODN).
OVA peptide (H-2K b restricted, SIINFEKL, aa 257-264) 26 , VSV peptide (H-2K b restricted, RGYVYGQL) 27 , OVA peptide (I-A b restricted , IINFEKLTEWTSSNVMEER, aa 258-276) 28 and VSV II peptide (I-A b -restricted, SSKAQVFEHPHIQDAASQL) 27 were purchased from
Research Genetics (Huntsville, AL). The following phosphorothioate-modified ODNs were synthesized: AE40 (5'-TTGGTCATCCATGGCTCT-3') and AE54 (5'-TGGTCATCCATGGCTCTA-3') correspond to previously described invariant chain 
RNA preparation
Cellular RNA was extracted using the RNeasy kit (Qiagen, Valencia, CA). mRNA was isolated from total RNA using MACS mRNA isolation kit (Miltenyi Biotec, Auburn, CA) .The plasmids, pGEM4Z/OVA/A64, pGEM4Z/GFP/A64 and pGEM4Z/Flu/A64, used for in vitro transcription of OVA, GFP and influenza (Flu, M1) mRNA respectively, were previously described 29 . Murine tyrosinase-related protein 2 (TRP-2) mRNA and a truncated form of OVA from which the first 40 aa were deleted were produced by in vitro transcription from a cDNA fragment amplified by RT-PCR. 
In vivo

RESULTS
We used two phosphorothioate-modified antisense oligonucleotides (ODNs) described by Qiu et al 23 to test whether invariant chain expression can be inhibited in murine DC. Surface expression of invariant chain (CD74) is significantly reduced in DC treated with antisense (Ii AS), but not control, ODNs, whereas a partial inhibition was seen when both intracellular and cell surface expression were measured ( Consistent with our observations, invariant chain independent class II expression on the cell surface was seen in DC and activated macrophages, but not in B cells 34, 35 . B.
IL-2 (pg/ml)
The presentation of MHC class I and class II chicken ovalbumin (OVA) epitopes is shown in epitopes by the OVA mRNA-transfected DC was determined using T-hybridomas specific to each epitope. No presentation of the class II epitope was seen with a truncated form of OVA (tOVA) from which the first 40 aa containing the leader sequence were removed ( Fig. 2A) . This is consistent with the observations that class II presentation of endogenous antigens is confined primarily to antigens which can access the endocytic compartments 14 . In contrast, the native secreted form of OVA is capable of processing the class II epitope for presentation to the class II (Fig 3D) . These observations show that immunization with Ii AS ODN treated DC extend the persistence of CTL precursors in the spleen of the immunized mice (Fig, 3C ) and induce a larger pool of memory CTL which can be reactivated by immunization (Fig. 3D) . (DC treated with control ODN) was enhanced in CD4 + T cell depleted mice whereas depletion of CD8 + T cells had no effect (Fig. 5) . CD4 + T cells are, therefore, the primary effectors of tumor inhibition in this model as has been seen in other studies [9] [10] [11] . Notably, depletion of CD8 + T cells abrogated the Ii AS ODN effect. This observation suggests that the antisense mediated inhibition of invariant chain expression enhances tumor inhibition by inducing a CD4 + T cell-dependent CD8 + T cell response. Additional studies using several tumor models will be required to determine the generality of this observation. It will be also important to determine the role of CD4 + and CD8 + T cells at the induction phase, by depleting the T cell subsets prior to immunization.
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006). To test whether Ii inhibition can also potentiate antitumor immunity directed against
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From natural tumor antigens, mice were immunized with TRP-2 mRNA or total B16/F10.9 tumor RNA. TRP-2 is a melanocyte specific ER-resident dominant tumor antigen in the B16/F10.9 melanoma tumor 37 . As shown in Figure 6B , the antitumor effect seen in tumor bearing mice immunized with either TRP-2 mRNA (p=0.0535) or B16/F10.9 tumor RNA transfected DC (p=0.03)was enhanced when the DC were treated with Ii AS, but not control, ODNs. Treatment of influenza matrix (Flu M1) mRNA transfected DC with Ii AS ODNs had no significant antitumor effect (Fig. 6A , p=0.9 and data not shown), suggesting that the effect of invariant chain inhibition was OVA antigen-specific. This, and the observation that Ii AS ODN treatment of DC transfected with tOVA mRNA, which is not capable of presenting class II epitopes ( 
B.
For personal use only. 5, 6 . Here we show that enhanced activation of OVA-specific CD4 + T cells in mice immunized with DC expressing reduced levels of invariant chain is accompanied by increased induction of CD8 + CTL (Fig. 3B) , extended persistence of a measurable CTL response (Fig. 3C ) and a larger pool of memory CTL that can be reactivated in vivo (Fig. 3D ). In addition, inhibition of invariant chain synthesis in DC correlates with enhanced tumor immunity (Figures 4-6 ). This was seen reproducibly using Invariant chain inhibition-mediated enhancement of class II presentation requires the translocation of endogenous antigens into the ER/endosomal compartment 14 which can be achieved by appending a lysosomal targeting signal to the carboxy end of the antigen 15 .
individually with the lysosomal targeting signal, the invariant chain inhibition strategy described here will be also applicable when undefined cell (tumor) derived antigenic mixtures are used, as illustrated in the case of immunotherapy with B16/F10.9 melanoma tumor RNA transfected DC (Fig. 6) . Conceivably, in this instance inhibition of invariant chain expression leads to enhanced stimulation of CD4 + T cell responses against a subset of tumor antigens, including perhaps TRP-2, which can access the endosomal compartment.
The strategy to enhance CD4 + T cell immunity described in this study is by no means limited to 
